NCT07248995 Contribution of Transthoracic and Transcranial Ultrasonography to the Titration of PEEP in Patients With ARDS and ABI
| NCT ID | NCT07248995 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Theodoros Schizodimos |
| Condition | Acute Respiratory Distress Syndrome (ARDS) |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2025-12-01 |
| Primary Completion | 2027-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2025-12-01 with a primary completion date of 2027-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The present study will investigate whether the combined use of lung and brain ultrasonography is useful in selecting the optimal positive end-expiratory pressure in mechanically ventilated critically ill patients with acute respiratory distress syndrome and acute brain injury, aiming at an individualized, brain-protective ventilation strategy.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years * Severe acute brain injury (e.g., traumatic brain injury, subarachnoid hemorrhage, intracerebral hemorrhage, acute ischemic stroke) * Development of ARDS (according to Berlin criteria) within the first 10 days of ICU admission Exclusion Criteria: * Severe chronic brain diseases * Brain tumor or central nervous system (CNS) infection * Severe chronic pulmonary or cardiovascular disease * Severe coagulopathy * Undergoing decompressive craniectomy * Lack of invasive neuromonitoring * Withdrawal of life-sustaining treatment * Poor acoustic window in ultrasound
Contact & Investigator
Theodoros Schizodimos, MD
PRINCIPAL INVESTIGATOR
2nd Intensive Care Unit, George Papanikolaou General Hospital of Thessaloniki
Frequently Asked Questions
Who can join the NCT07248995 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Acute Respiratory Distress Syndrome (ARDS). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07248995 currently recruiting?
Yes, NCT07248995 is actively recruiting participants. Contact the research team at teoschizo@gmail.com for enrollment information.
Where is the NCT07248995 trial being conducted?
This trial is being conducted at Thessaloniki, Greece.
Who is sponsoring the NCT07248995 clinical trial?
NCT07248995 is sponsored by Theodoros Schizodimos. The principal investigator is Theodoros Schizodimos, MD at 2nd Intensive Care Unit, George Papanikolaou General Hospital of Thessaloniki. The trial plans to enroll 30 participants.